Fidelity Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-305,225
| Closed | -$31.1M | – | 5606 |
|
|
2023
Q2 | $31.1M | Buy |
305,225
+180,740
| +145% | +$17.1M | ﹤0.01% | 1457 |
|
|
2023
Q1 | $11.3M | Sell |
124,485
-259,591
| -68% | -$15.2M | ﹤0.01% | 1826 |
|
|
2022
Q4 | $14.6M | Sell |
384,076
-131,805
| -26% | -$4.54M | ﹤0.01% | 1746 |
|
|
2022
Q3 | $13M | Sell |
515,881
-13,669
| -3% | -$379K | ﹤0.01% | 1787 |
|
|
2022
Q2 | $16.1M | Buy |
529,550
+114,889
| +28% | +$3.43M | ﹤0.01% | 1740 |
|
|
2022
Q1 | $13.6M | Buy |
414,661
+184,021
| +80% | +$5.46M | ﹤0.01% | 1988 |
|
|
2021
Q4 | $6.08M | Sell |
230,640
-587,025
| -72% | -$45.4M | ﹤0.01% | 2300 |
|
|
2021
Q3 | $82.3M | Buy |
817,665
+67,732
| +9% | +$7.94M | 0.01% | 1189 |
|
|
2021
Q2 | $106M | Buy |
749,933
+689,001
| +1,131% | +$77.8M | 0.01% | 1099 |
|
|
2021
Q1 | $6.08M | Sell |
60,932
-424,100
| -87% | -$49.5M | ﹤0.01% | 2204 |
|
|
2020
Q4 | $60M | Sell |
485,032
-7,384
| -1% | -$970K | 0.01% | 1253 |
|
|
2020
Q3 | $48M | Sell |
492,416
-374,432
| -43% | -$46.8M | ﹤0.01% | 1211 |
|
|
2020
Q2 | $135M | Buy |
866,848
+140,478
| +19% | +$21.4M | 0.01% | 750 |
|
|
2020
Q1 | $105M | Buy |
726,370
+367,402
| +102% | +$70.9M | 0.01% | 740 |
|
|
2019
Q4 | $73.4M | Buy |
358,968
+248,565
| +225% | +$45.3M | 0.01% | 1040 |
|
|
2019
Q3 | $8.86M | Buy |
110,403
+61,606
| +126% | +$5.23M | ﹤0.01% | 1878 |
|
|
2019
Q2 | $4.6M | Sell |
48,797
-112,900
| -70% | -$9.75M | ﹤0.01% | 2116 |
|
|
2019
Q1 | $13.8M | Sell |
161,697
-145,900
| -47% | -$12.1M | ﹤0.01% | 1741 |
|
|
2018
Q4 | $17.3M | Sell |
307,597
-69,000
| -18% | -$4.21M | ﹤0.01% | 1615 |
|
|
2018
Q3 | $30.8M | Sell |
376,597
-92,393
| -20% | -$6.51M | ﹤0.01% | 1503 |
|
|
2018
Q2 | $16.4M | Sell |
468,990
-160,861
| -26% | -$4.9M | ﹤0.01% | 1795 |
|
|
2018
Q1 | $12.9M | Sell |
629,851
-29,440
| -4% | -$758K | ﹤0.01% | 1883 |
|
|
2017
Q4 | $18.7M | Sell |
659,291
-13,600
| -2% | -$379K | ﹤0.01% | 1747 |
|
|
2017
Q3 | $20.9M | Buy |
672,891
+258,400
| +62% | +$7.77M | ﹤0.01% | 1680 |
|
|
2017
Q2 | $13.1M | Buy |
414,491
+176,885
| +74% | +$4.35M | ﹤0.01% | 1843 |
|
|
2017
Q1 | $5.38M | Buy |
237,606
+68,600
| +41% | +$1.69M | ﹤0.01% | 2155 |
|
|
2016
Q4 | $3.69M | Sell |
169,006
-310,018
| -65% | -$7.84M | ﹤0.01% | 2255 |
|
|
2016
Q3 | $12.6M | Sell |
479,024
-70,976
| -13% | -$1.41M | ﹤0.01% | 1891 |
|
|
2016
Q2 | $10.9M | Buy |
+550,000
| New | +$10.7M | ﹤0.01% | 1926 |
|
Other funds holding RETA
Fidelity Investments's RETA Position: Q3 2023 in Review
Fidelity Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 305,225 shares — an estimated $31.1M sold.
Fidelity Investments first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $135M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Fidelity Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Fidelity Investments sold 305,225 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $31.1M.
- Fidelity Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Fidelity Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $135M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.